{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:49:59Z","timestamp":1764510599501,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T00:00:00Z","timestamp":1516060800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00277-018-3243-7","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T17:07:41Z","timestamp":1516122461000},"page":"821-829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review"],"prefix":"10.1007","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0432-9706","authenticated-orcid":false,"given":"Emanuele","family":"Cencini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Lauria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,16]]},"reference":[{"key":"3243_CR1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"S Swerdlow","year":"2008","unstructured":"Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, Thiele J, Vardiman J (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon"},{"issue":"8","key":"3243_CR2","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/ajg.2009.314","volume":"104","author":"A Zullo","year":"2009","unstructured":"Zullo A, Hassan C, Andriani A, Cristofari F, De Francesco V, Ierardi E, Tomao S, Morini S, Vaira D (2009) Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol 104(8):1932\u20131937. \n                    https:\/\/doi.org\/10.1038\/ajg.2009.314","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"3243_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.clml.2014.07.002","volume":"15","author":"C Tarella","year":"2015","unstructured":"Tarella C, Arcaini L, Baldini L, Barosi G, Billio A, Marchetti M, Rambaldi A, Vitolo U, Zinzani PL, Tura S (2015) Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). Clin Lymphoma Myeloma Leuk 15(2):75\u201385. \n                    https:\/\/doi.org\/10.1016\/j.clml.2014.07.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"3243_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3322\/caac.21330","volume":"66","author":"M Raderer","year":"2016","unstructured":"Raderer M, Kiesewetter B, Ferreri AJ (2016) Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin 66(2):153\u2013171. \n                    https:\/\/doi.org\/10.3322\/caac.21330","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"3243_CR5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1634\/theoncologist.2015-0109","volume":"20","author":"B Kiesewetter","year":"2015","unstructured":"Kiesewetter B, Ferreri AJ, Raderer M (2015) Chemoimmunotherapy for mucosa-associated lymphoid tissue-type lymphoma: a review of the literature. Oncologist 20(8):915\u2013925. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2015-0109","journal-title":"Oncologist"},{"issue":"9","key":"3243_CR6","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99(9):706\u2013714. \n                    https:\/\/doi.org\/10.1093\/jnci\/djk152","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"3243_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","volume":"31","author":"E Zucca","year":"2013","unstructured":"Zucca E, Conconi A, Laszlo D, L\u00f3pez-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C (2013) Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol 31(5):565\u2013572. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.40.6272","journal-title":"J Clin Oncol"},{"issue":"9873","key":"3243_CR8","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, D\u00fcrk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent Lymphomas (StiL) (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u20131210. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(12)61763-2","journal-title":"Lancet"},{"issue":"15","key":"3243_CR9","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1182\/blood-2017-07-795302","volume":"130","author":"A Salar","year":"2017","unstructured":"Salar A, Domingo-Domenech E, Panizo C, Nicol\u00e1s C, Bargay J, Munta\u00f1ola A, Canales M, Bello JL, Sancho JM, Tom\u00e1s JF, Rodr\u00edguez MJ, Pe\u00f1alver J, Grande C, S\u00e1nchez-Blanco JJ, Palomera L, Arranz R, Conde E, Garc\u00eda M, Garc\u00eda JF, Caballero D, Montalb\u00e1n C (2017) Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood 130(15):1772\u20131774. \n                    https:\/\/doi.org\/10.1182\/blood-2017-07-795302","journal-title":"Blood"},{"key":"3243_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/hon.2437_130","volume":"35","author":"I Flinn","year":"2017","unstructured":"Flinn I, van der Jagt R, Chang J, Wood P, Hawkins T, MacDonald D, Trotman J, Simpson D, Kolibaba K, Issa S, Hallmann D, Chen L, Burke JM (2017) First-line treatment of iNHL or MCL patients with BR or R-CHOP\/R-CVP: results of the BRIGHT 5-year follow-up study. Hematol Oncol 35:140\u2013141. \n                    https:\/\/doi.org\/10.1002\/hon.2437_130","journal-title":"Hematol Oncol"},{"issue":"14","key":"3243_CR11","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trn\u011bn\u00fd M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377(14):1331\u20131344. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1614598","journal-title":"N Engl J Med"},{"key":"3243_CR12","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2017.35.15_suppl.7501","volume":"35","author":"MJ Rummel","year":"2017","unstructured":"Rummel MJ, Maschmeyer G, Ganser A, Heider A, von Gruenhagen U, Losem C, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, D\u00fcrk HA, Ballo H, Stauch M, Blau W, Burchardt A, Barth J, Kauff F, Brugger W (2017) Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study. J Clin Oncol 35:7501\u20137501","journal-title":"J Clin Oncol"},{"issue":"3","key":"3243_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/hon.2151","volume":"33","author":"PL Zinzani","year":"2015","unstructured":"Zinzani PL, Pellegrini C, Broccoli A, Gandolfi L, Stefoni V, Casadei B, Maglie R, Argnani L, Pileri S (2015) Fludarabine-mitoxantrone-rituximab regimen in untreated indolent non-follicular non-Hodgkin\u2019s lymphoma: experience on 143 patients. Haematol Oncologia 33(3):141\u2013146. \n                    https:\/\/doi.org\/10.1002\/hon.2151","journal-title":"Haematol Oncologia"},{"issue":"4","key":"3243_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/hon.2039","volume":"31","author":"PL Zinzani","year":"2013","unstructured":"Zinzani PL, Pellegrini C, Gandolfi L, Casadei B, Derenzini E, Broccoli A, Quirini F, Argnani L, Pileri S, Celli M, Fanti S, Poletti V, Stefoni V, Baccarani M (2013) Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. Haematol Oncologia 31(4):183\u2013188. \n                    https:\/\/doi.org\/10.1002\/hon.2039","journal-title":"Haematol Oncologia"},{"issue":"4","key":"3243_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3109\/10428194.2013.826354","volume":"55","author":"A Fabbri","year":"2014","unstructured":"Fabbri A, Cencini E, Rigacci L, Bartalucci G, Puccini B, Dottori R, Gozzetti A, Bosi A, Bocchia M (2014) Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma 55(4):781\u2013785. \n                    https:\/\/doi.org\/10.3109\/10428194.2013.826354","journal-title":"Leuk Lymphoma"},{"key":"3243_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/annonc\/mdt343","volume":"24","author":"E Zucca","year":"2013","unstructured":"Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C, Raderer M, LAdetto M, on behalf of the ESMO Guidelines Working Group (2013) Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:144\u2013148","journal-title":"Ann Oncol"},{"issue":"5","key":"3243_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/oxfordjournals.annonc.a058869","volume":"5","author":"A Rohatiner","year":"1994","unstructured":"Rohatiner A, d'Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, Lister TA, Norton A, Salem P, Shipp M (1994) Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 5(5):397\u2013400. \n                    https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a058869","journal-title":"Ann Oncol"},{"issue":"4","key":"3243_CR18","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-L\u00f3pez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244\u20131253. \n                    https:\/\/doi.org\/10.1200\/JCO.1999.17.4.1244","journal-title":"J Clin Oncol"},{"issue":"13","key":"3243_CR19","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1001\/jama.1983.03330370053031","volume":"249","author":"JA Hanley","year":"1983","unstructured":"Hanley JA, Lippman-Hand A (1983) If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA 249(13):1743\u20131745. \n                    https:\/\/doi.org\/10.1001\/jama.1983.03330370053031","journal-title":"JAMA"},{"key":"3243_CR20","doi-asserted-by":"publisher","unstructured":"Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, Martelli M, Laszlo D, Coiffier B, Lopez Guillermo A, Torri V, Cavalli F, Johnson PW, Zucca E (2017) A MALT lymphoma prognostic index generated from the dataset of the IELSG-19 prospective clinical trial. Blood 130(12):1409\u20131417. \n                    https:\/\/doi.org\/10.1182\/blood.2017.03.771915","DOI":"10.1182\/blood.2017.03.771915"},{"issue":"10","key":"3243_CR21","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1200\/JCO.1995.13.10.2524","volume":"13","author":"P Hammel","year":"1995","unstructured":"Hammel P, Haioun C, Chaumette MT, Gaulard P, Divine M, Reyes F, Delchier JC (1995) Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 13(10):2524\u20132529. \n                    https:\/\/doi.org\/10.1200\/JCO.1995.13.10.2524","journal-title":"J Clin Oncol"},{"issue":"18","key":"3243_CR22","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1200\/JCO.2002.05.117","volume":"20","author":"G J\u00e4ger","year":"2002","unstructured":"J\u00e4ger G, Neumeister P, Brezinschek R, Hinterleitner T, Fiebiger W, Penz M, Neumann HJ, Mlineritsch B, DeSantis M, Quehenberger F, Chott A, Beham-Schmid C, H\u00f6fler G, Linkesch W, Raderer M (2002) Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 20(18):3872\u20133877. \n                    https:\/\/doi.org\/10.1200\/JCO.2002.05.117","journal-title":"J Clin Oncol"},{"issue":"8","key":"3243_CR23","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","volume":"102","author":"A Conconi","year":"2003","unstructured":"Conconi A, Martinelli G, Thi\u00e9blemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell\u2019Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E (2003) Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 102(8):2741\u20132745. \n                    https:\/\/doi.org\/10.1182\/blood-2002-11-3496","journal-title":"Blood"},{"issue":"9","key":"3243_CR24","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","volume":"23","author":"G Martinelli","year":"2005","unstructured":"Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E (2005) Clinical activity of rituximab in gastric marginal zone non-Hodgkin\u2019s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 23(9):1979\u20131983. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.08.128","journal-title":"J Clin Oncol"},{"issue":"22","key":"3243_CR25","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1002\/cncr.24605","volume":"115","author":"A Salar","year":"2009","unstructured":"Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalb\u00e1n C (2009) Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer 115(22):5210\u20135217. \n                    https:\/\/doi.org\/10.1002\/cncr.24605","journal-title":"Cancer"},{"issue":"3","key":"3243_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/hon.2105","volume":"32","author":"D Aguiar-Bujanda","year":"2014","unstructured":"Aguiar-Bujanda D, Llorca-M\u00e1rtinez I, Rivero-Vera JC, Blanco-S\u00e1nchez MJ, Jim\u00e9nez-Gallego P, Mori-De Santiago M, Limeres-Gonzalez MA, Cabrera-Marrero JC, Hern\u00e1ndez-Sosa M, Galv\u00e1n-Ru\u00edz S, Hern\u00e1ndez-Sarmiento S, Saura Grau S, Bohn-Sarmiento U (2014) Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone. Haematol Oncologia 32(3):139\u2013144. \n                    https:\/\/doi.org\/10.1002\/hon.2105","journal-title":"Haematol Oncologia"},{"issue":"1","key":"3243_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1385\/MO:22:1:057","volume":"22","author":"A Avil\u00e9s","year":"2005","unstructured":"Avil\u00e9s A, Nambo MJ, Neri N, Talavera A, Cleto S (2005) Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med Oncol 22(1):57\u201362. \n                    https:\/\/doi.org\/10.1385\/MO:22:1:057","journal-title":"Med Oncol"},{"issue":"5","key":"3243_CR28","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3109\/10428194.2012.729832","volume":"54","author":"M L\u00e9vy","year":"2013","unstructured":"L\u00e9vy M, Copie-Bergman C, Amiot A, Dupuis J, Le Baleur Y, Belhadj K, H\u00e9mery F, Sobhani I, Delfau-Larue MH, Leroy K, Haioun C, Delchier JC (2013) Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study. Leuk Lymphoma 54(5):940\u2013944. \n                    https:\/\/doi.org\/10.3109\/10428194.2012.729832","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"3243_CR29","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3109\/10428190903431820","volume":"51","author":"M L\u00e9vy","year":"2010","unstructured":"L\u00e9vy M, Copie-Bergman C, Molinier-Frenkel V, Riou A, Haioun C, Gaulard P, Delfau-Larue MH, Sobhani I, Leroy K, Delchier JC (2010) Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up. Leuk Lymphoma 51(2):284\u2013290. \n                    https:\/\/doi.org\/10.3109\/10428190903431820","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"3243_CR30","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","volume":"1","author":"A Salar","year":"2014","unstructured":"Salar A, Domingo-Domenech E, Panizo C, Nicol\u00e1s C, Bargay J, Munta\u00f1ola A, Canales M, Bello JL, Sancho JM, Tom\u00e1s JF, Rodr\u00edguez MJ, Pe\u00f1alver FJ, Grande C, S\u00e1nchez-Blanco JJ, Palomera L, Arranz R, Conde E, Garc\u00eda M, Garc\u00eda JF, Caballero D, Montalb\u00e1n C, Grupo Espa\u00f1ol de Linfomas\/Trasplante de M\u00e9dula \u00d3sea (GELTAMO) (2014) First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol 1(3):e104\u2013e111. \n                    https:\/\/doi.org\/10.1016\/S2352-3026(14)00021-0","journal-title":"Lancet Haematol"},{"issue":"6","key":"3243_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/apt.12635","volume":"39","author":"A Amiot","year":"2014","unstructured":"Amiot A, L\u00e9vy M, Copie-Bergman C, Dupuis J, Szablewski V, Le Baleur Y, Baia M, Belhadj K, Sobhani I, Leroy K, Haioun C, Delchier JC (2014) Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study. Aliment Pharmacol Ther 39(6):619\u2013628. \n                    https:\/\/doi.org\/10.1111\/apt.12635","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"3243_CR32","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1080\/10428190701457949","volume":"48","author":"IS Lossos","year":"2007","unstructured":"Lossos IS, Morgensztern D, Blaya M, Alencar A, Pereira D, Rosenblatt J (2007) Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma. Leuk Lymphoma 48(8):1630\u20131632. \n                    https:\/\/doi.org\/10.1080\/10428190701457949","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"3243_CR33","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","volume":"35","author":"E Zucca","year":"2017","unstructured":"Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zach\u00e9e P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C (2017) Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol 35(17):1905\u20131912. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.70.6994","journal-title":"J Clin Oncol"},{"issue":"2","key":"3243_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3324\/haematol.2012.072587","volume":"98","author":"M Troch","year":"2013","unstructured":"Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, M\u00fcllauer L, Greil R, Raderer M (2013) Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumourtherapie. Haematologica 98(2):264\u2013268. \n                    https:\/\/doi.org\/10.3324\/haematol.2012.072587","journal-title":"Haematologica"},{"issue":"19","key":"3243_CR35","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123(19):2944\u20132952. \n                    https:\/\/doi.org\/10.1182\/blood-2013-11-531327","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3243-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3243-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3243-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T20:04:24Z","timestamp":1547582664000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3243-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,16]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["3243"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3243-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2018,1,16]]},"assertion":[{"value":"24 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}